Stay Up to Date! Like us on Facebook  and Twitter  for the latest news and announcements    

Stealth BioTherapeutics webinar

Please join MitoAction, Foundation for Mitochondrial Medicine, and UMDF for a special presentation by Stealth BioTherapeutics on Friday, Aug. 11, 2017 at 12 p.m. Eastern time.

Stealth's CEO Reenie McCarthy and Chief Clinical Development Officer Jim Carr will share updates on Stealth's second clinical trial for mitochondrial myopathy, the MMPOWER-2 study. 

Join us for this free webinar to learn more about:

  • Safety and tolerability data of elamipretide (previously known as Bendavia) from the MMPOWER-2 study
  • Tests and assessments used to measure efficacy of elamipretide in the MMPOWER-2 trial
  • Endpoints and outcomes from the MMPOWER-2 trial for people ages 16-65 with genetically-confirmed mitochondrial myopathy
  • Future Stealth BT studies evaluating elamipretide and mitochondrial myopathy

All are welcome and encouraged to listen to this live presentation. An opportunity to submit questions online will be provided during the live webinar.

 Stealth BioTherapeutics patient/community update on MMPOWER-2 and RePOWER Primary Mitochondrial Myopathy clinical trials

Friday, Aug. 11, 2017 at 12:00 P.M. EDT

Register now!

After registering, you will receive a confirmation email containing information about joining the webinar.

View System Requirements

For more information, please read the community press release: "Stealth BioTherapeutics shares promising data from Mitochondrial Myopathy trial."

Click here for more information about RePOWER.

No votes yet